What Are the Biomarkers for Immunotherapy in SCLC?
SCLC
SCLC-I subtype
biomarkers
programmed death ligand 1
serum anti-neuronal nuclear antibodies
tumour microenvironment
tumour mutational burden
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Oct 2021
15 Oct 2021
Historique:
received:
19
08
2021
revised:
12
10
2021
accepted:
12
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
20
1
2022
Statut:
epublish
Résumé
Small-cell lung cancer (SCLC) is an aggressive malignancy that exhibits a rapid doubling time, a high growth fraction, and the early development of widespread metastases. The addition of immune checkpoint inhibitors to first-line chemotherapy represents the first significant improvement of systemic therapy in several decades. However, in contrast to its effects on non-SCLC, the advantageous effects of immunotherapy addition are modest in SCLC. In particular, only a small number of SCLC patients benefit from immune checkpoint inhibitors. Additionally, biomarkers selection is lacking for SCLC, with clinical trials largely focusing on unselected populations. Here, we review the data concerning the major biomarkers for immunotherapy, namely, programmed death ligand 1 expression and tumour mutational burden. Furthermore, we explore other potential biomarkers, including the role of the immune microenvironment in SCLC, the role of genetic alterations, and the potential links between neurological paraneoplastic syndromes, serum anti-neuronal nuclear antibodies, and outcomes in SCLC patients treated with immunotherapy.
Identifiants
pubmed: 34681779
pii: ijms222011123
doi: 10.3390/ijms222011123
pmc: PMC8538776
pii:
doi:
Substances chimiques
Biomarkers, Pharmacological
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
Am Soc Clin Oncol Educ Book. 2018 May 23;38:682-695
pubmed: 30231367
Transl Lung Cancer Res. 2018 Feb;7(1):32-49
pubmed: 29535911
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
J Thorac Oncol. 2020 Apr;15(4):618-627
pubmed: 31870883
Ann Oncol. 2016 Apr;27(4):732-8
pubmed: 26802161
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Expert Opin Biol Ther. 2019 May;19(5):423-432
pubmed: 30855195
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Thorac Oncol. 2019 Nov;14(11):1878-1880
pubmed: 31668313
Lung Cancer. 2007 Nov;58(2):291-5
pubmed: 17574297
Lancet. 1993 Jan 2;341(8836):21-2
pubmed: 8093269
J Clin Oncol. 2021 Feb 20;39(6):619-630
pubmed: 33439693
J Neurooncol. 2016 Oct;130(1):19-29
pubmed: 27436101
Lancet. 1999 Jan 9;353(9147):117-8
pubmed: 10023900
Thorac Cancer. 2020 Jun;11(6):1578-1586
pubmed: 32286017
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
Cancer Cell. 2021 Mar 8;39(3):346-360.e7
pubmed: 33482121
J Clin Oncol. 2017 Dec 1;35(34):3823-3829
pubmed: 28813164
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
J Neurol Neurosurg Psychiatry. 2021 Mar 30;:
pubmed: 33785578
Onco Targets Ther. 2020 Jul 03;13:6475-6483
pubmed: 32753888
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496
pubmed: 27185375
J Immunother Cancer. 2021 May;9(5):
pubmed: 34006632
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
J Thorac Oncol. 2019 Jul;14(7):1286-1295
pubmed: 31078775
J Thorac Oncol. 2019 Nov;14(11):1970-1981
pubmed: 31201935
Neurology. 2015 Jul 21;85(3):235-9
pubmed: 26109714
J Thorac Oncol. 2015 Mar;10(3):426-30
pubmed: 25384063
J Thorac Oncol. 2018 Sep;13(9):1393-1399
pubmed: 29775808
Clin Cancer Res. 2016 Feb 1;22(3):609-20
pubmed: 26420858
J Thorac Oncol. 2019 May;14(5):914-923
pubmed: 30735815
Lung Cancer. 2006 Aug;53(2):249-52
pubmed: 16790292
J Thorac Oncol. 2016 Sep;11(9):1511-21
pubmed: 27296105
Cancers (Basel). 2020 Sep 04;12(9):
pubmed: 32899891
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33082168
Cancer. 2015 Mar 1;121(5):664-72
pubmed: 25336398
Transl Lung Cancer Res. 2020 Aug;9(4):1483-1495
pubmed: 32953520
Clin Cancer Res. 2000 May;6(5):1875-81
pubmed: 10815910
Eur J Cancer. 2015 Feb;51(3):421-6
pubmed: 25582496
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
JTO Clin Res Rep. 2021 May 18;2(7):100184
pubmed: 34590034
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
J Clin Oncol. 2020 Jul 20;38(21):2369-2379
pubmed: 32468956
Eur J Cancer. 2018 Sep;101:191-200
pubmed: 30077124
Lung Cancer. 2007 Sep;57(3):399-403
pubmed: 17397962
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34362829
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
J Thorac Oncol. 2019 May;14(5):903-913
pubmed: 30664989
J Clin Oncol. 2009 Sep 10;27(26):4260-7
pubmed: 19667272
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
J Thorac Oncol. 2020 Apr;15(4):520-540
pubmed: 32018053
Oncoimmunology. 2019 Mar 27;8(6):e1593810
pubmed: 31069160
Lung Cancer. 2010 Dec;70(3):335-9
pubmed: 20371131
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196